Back In Bay Area: Biotech CEO Takes On New Challenge With Startup Targeting HIV
"I found [Vir Biotechnology] compelling because of the need and the public health issues around the world — in the developing world and the developed world. So there's a human need and a financial return," former Exelixis Inc. CEO George Scangos says.
San Francisco Business Times:
Biotech Icon George Scangos Returns To Bay Area With Big Startup
George Scangos is back in the Bay Area, targeting HIV and other infectious diseases.The former Exelixis Inc. CEO — who spent the past six-plus years leading Boston-area biotech Biogen Inc. — is CEO of Vir Biotechnology Inc. The startup is backed by $150 million from Arch Venture Partners, an equity investment from the Bill & Melinda Gates Foundation and other unspecified investors. (Leuty, 1/6)
In other news —